Platelet aggregation pathway components

The "platelet aggregation pathway components" include a range of proteins, receptors, and enzymes that mediate the process of platelet aggregation, an essential step in blood clot formation. Key molecules in this pathway include receptors for ADP (P2Y1, P2Y12), thrombin (PAR1, PAR4), thromboxane A2 (TXA2R), collagen (glycoprotein VI), integrin αIIbβ3 (GPIIb/IIIa), and several intracellular signal transducers like phospholipase C, protein kinase C, and others. Upon vascular injury, platelets are activated by these agonists and adhere to each other via receptor-ligand interactions, forming a hemostatic plug. Disruption or over-activation of this pathway leads to thrombotic or bleeding disorders. Its components are major targets of current antiplatelet therapeutics, and new agents continue to focus on signaling nodes within this pathway to reduce thrombotic risk without excessive bleeding[3][4][5][6][8]. Note: For structured data extraction or target-based bioinformatics workflows, "Platelet aggregation pathway components" should be decomposed into its constituent molecular targets (e.g., P2Y12, GPIIb/IIIa, PAR1), with information provided separately for each. As is, this term is not a valid single canonical target for molecular mapping or drug discovery pipelines[3][4][6].

Other names

Platelet aggregation pathwayPlatelet activation pathwayPlatelet aggregation signalingPlatelet aggregation mediators

COX-1 inhibitors (e.g., aspirin inhibit thromboxane A2 synthesis); P2Y12 antagonists (block ADP-mediated platelet activation: clopidogrel, prasugrel, ticagrelor); GPIIb/IIIa inhibitors (block fibrinogen binding and platelet aggregation: abciximab, eptifibatide, tirofiban); PAR1 antagonists (block thrombin-mediated platelet activation); Natural product inhibitors (flavonoids, alkaloids, etc.)